Partnerships & Alliances
Filter News
Found 48,128 articles
-
INVO Bioscience Expands Distribution of INVOcell Into the Pakistan Infertility Market with Galaxy Pharma Ltd.
1/15/2021
- Signs distribution agreement with Galaxy Pharma Ltd., the clear market leader of infertility products and services in Pakistan - Seeks to expand access to infertility care in the fifth most populous country in the world, Pakistan, with approximately 212 million people
-
Poxel Regains Imeglimin Rights From Metavant
1/14/2021
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that, as part of the previously communicated decision by Metavant not to advance Imeglimin into a Phase 3 program for strategic reasons
-
Pulmonary Fibrosis Foundation Announces Sponsorship by United Therapeutics
1/14/2021
The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) education and advocacy organization, has announced United Therapeutics' sponsorship of the PFF Registry, a research resource that tracks clinical data, blood samples and patient-reported outcomes from individuals living with PF nationwide.
-
Relay Medical and Glow LifeTech Report on Successful Phase II Clinical Results For COVID-19 Treatment Candidate Based On Its MyCell Technology™
1/14/2021
Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), a developer of MedTech innovation, and Glow LifeTech Ltd. (“Glow”), a private company in which Relay holds a significant equity interest, are pleased to report on developments related to Glow’s MyCell Technology™ (“MyCell”).
-
Fuse Medical, Inc. Enters Into Marketing Agreement With CarePICS Telehealth
1/14/2021
Fuse Medical, Inc. (OTCPINK: FZMD) (“Fuse” or the “Company”) an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced today an agreement with CarePICS, the latest resource addition to Fuse’s comprehensive portfolio and biologics product offerings for wound care.
-
etectRx Announces Agreement to Advance Digital Sensors for Medication Adherence in Combination with Prescription Digital Therapeutics
1/14/2021
Digital health company, etectRx , Inc., announced today that it has entered into an agreement with Pear Therapeutics, Inc. to develop up to two product candidates in the Central Nervous System (CNS) space combining Prescription Digital Therapeutics (PDTs) and adherence sensors. The collaboration is the first of its kind to ex
-
Charles River Partners with JADE Biomedical to Expand Biologics Capabilities
1/14/2021
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with JADE Biomedical (JADE) , a provider of end-to-end quality management services for the biopharmaceutical industry. The partnership will expand Charles River’s biologics testing capabilities
-
Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin
1/14/2021
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a sponsored research agreement and an exclusive option to license agreement with North Carolina State University (“NC State”) to develop a novel biosynthetic version of psilocybin based on a natural biosynth
-
Nucleai and Debiopharm Launch Research Collaboration Utilizing Nucleai's Ai-Powered Biomarker Platform
1/14/2021
Nucleai (www.Nucleaimd.com), a global provider in pathology-based biomarker discovery, and Debiopharm (www.debiopharm.com), a Swiss-based biopharmaceutical company specializing in drug development, announced that they have entered into a long-term collaboration to leverage Nucleai's artificial intelligence (AI) -powered biomarker research & discovery platform for one of Debiopharm's clinical stage oncology assets.
-
Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
1/14/2021
-- Project aims to standardize MRD data generation, assessment and accelerate AML clinical trial programs bringing novel therapies to patients in need faster --
-
CareMetx, General Atlantic and The Vistria Group Announce Strategic Growth Partnership
1/14/2021
Significant investment from General Atlantic and The Vistria Group positions CareMetx for continued growth in supporting patient access to innovative therapies
-
Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program
1/14/2021
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an agreement with Lentigen Technology, Inc. (“Lentigen”), a wholly-owned subsidiary of Miltenyi Biotec B.V. & Co. KG, to manufacture lentiviral vectors for Oncternal’s investigational ROR1-targeting CAR-T cell therapy program.
-
Fujifilm and the Center for Advanced Biological Innovation and Manufacturing Announce $76M in Funding for Manufacturing and Innovation Center
1/14/2021
FUJIFILM Corporation (COO: Kenji Sukeno ) and the Center for Advanced Biological Innovation and Manufacturing (CABIM), today announced that it has secured $76 million in financing and signed a lease for a 40,000 square-foot site in Watertown, Massachusetts at The Arsenal on the Charles , owned and operated by Alexandria Real Estate Eq
-
Bola Technologies, Inc. and Henry Schein One Announce Partnership
1/14/2021
Bola Technologies, Inc. (Bola AI), a leading provider of Voice-AI technology for healthcare and dental care professionals, announced today a partnership with Henry Schein One to distribute versions of Bola AI's Voice Perio that integrate with the Dentrix® and cloud-based Dentrix Ascend® practice management systems
-
The two companies will work together to use dendritic cells to develop immune tolerance.
-
In an interview with BioSpace, Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, outlined Bayer’s thought process for opening its purse strings and diving into the deep end of the cell and gene therapy space.
-
Major players in the biotech industry are moving full steam ahead in their 2021 operations goals despite the ongoing pandemic, with global pharmaceutical giant Takeda being no exception.
-
NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials
1/13/2021
Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no other approved treatment options In initial Cancer Moonshot QUILT trials of haNK and avelumab (PD-L1 checkpoint inhibitor) completed in 2019, median overall survival rate more than doubled compared to historical controls (eight months versus three months)
-
Blue Cross Blue Shield of Massachusetts Partners with The Dimock Center on COVID-19 Vaccination Video
1/13/2021
Blue Cross Blue Shield of Massachusetts ("Blue Cross") has partnered with The Dimock Center to produce a new public health messaging video to support the COVID-19 vaccination effort.
-
CHOP and Penn Researchers Identify Nanoparticles that Could Be Used in Therapeutic mRNA Delivery before Birth
1/13/2021
--Study demonstrates the efficacy and therapeutic potential of select ionizable lipid nanoparticles for delivering mRNA to treat genetic diseases before birth--